JPWO2019144079A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019144079A5
JPWO2019144079A5 JP2020539792A JP2020539792A JPWO2019144079A5 JP WO2019144079 A5 JPWO2019144079 A5 JP WO2019144079A5 JP 2020539792 A JP2020539792 A JP 2020539792A JP 2020539792 A JP2020539792 A JP 2020539792A JP WO2019144079 A5 JPWO2019144079 A5 JP WO2019144079A5
Authority
JP
Japan
Prior art keywords
mtg
monothioglycerol
ascorbic acid
combination
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020539792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511326A (ja
JP2021511326A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/014422 external-priority patent/WO2019144079A1/en
Publication of JP2021511326A publication Critical patent/JP2021511326A/ja
Publication of JPWO2019144079A5 publication Critical patent/JPWO2019144079A5/ja
Publication of JP2021511326A5 publication Critical patent/JP2021511326A5/ja
Pending legal-status Critical Current

Links

JP2020539792A 2018-01-22 2019-01-21 ブプレノルフィンの徐放送達のための薬学的組成物 Pending JP2021511326A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862620317P 2018-01-22 2018-01-22
US62/620,317 2018-01-22
PCT/US2019/014422 WO2019144079A1 (en) 2018-01-22 2019-01-21 Pharmaceutical composition for sustained release delivery of buprenorphine

Publications (3)

Publication Number Publication Date
JP2021511326A JP2021511326A (ja) 2021-05-06
JPWO2019144079A5 true JPWO2019144079A5 (https=) 2022-01-31
JP2021511326A5 JP2021511326A5 (https=) 2022-01-31

Family

ID=67301573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020539792A Pending JP2021511326A (ja) 2018-01-22 2019-01-21 ブプレノルフィンの徐放送達のための薬学的組成物

Country Status (9)

Country Link
US (1) US11419866B2 (https=)
EP (1) EP3743072B1 (https=)
JP (1) JP2021511326A (https=)
CN (1) CN112236142A (https=)
AU (1) AU2019209416A1 (https=)
CA (1) CA3089114A1 (https=)
ES (1) ES2965836T3 (https=)
TW (1) TW201936191A (https=)
WO (1) WO2019144079A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230080811A1 (en) * 2020-01-14 2023-03-16 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Long-acting ropivacaine pharmaceutical composition, preparation method therefor and use thereof
CN113117092A (zh) * 2020-01-14 2021-07-16 中国科学院上海药物研究所 一种非水缓释递药系统
WO2022175974A1 (en) * 2021-02-18 2022-08-25 Navin Saxena Research And Technology Private Limited Non-aqueous injectable composition for sustained release of buprenorphine and use thereof
IL317873A (en) * 2022-06-24 2025-02-01 Alar Pharmaceuticals Inc Stable pharmaceutical composition of buprenorphine and method of preparation and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8533582A (en) * 1981-07-10 1984-01-12 Reckitt & Colman Products Limited Stable solutions of buprenorphine
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
IT1302682B1 (it) 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
DE60329515D1 (de) 2002-10-25 2009-11-12 Euro Celtique Sa Analoga und prodrugs von buprenorphin
CN1263760C (zh) 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法,以及长效作用镇痛药学组合物
WO2005117830A1 (en) * 2004-06-04 2005-12-15 Camurus Ab Liquid depot formulations
RU2008124805A (ru) * 2005-11-21 2009-12-27 Шеринг-Плоу Лтд. (CH) Фармацевтические композиции, содержащие бупренорфин
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
EP2262367A4 (en) * 2008-03-08 2011-04-20 Theraquest Biosciences Inc PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE
WO2009148503A2 (en) 2008-05-30 2009-12-10 Namedepot.Com, Inc. Method and system for providing online services and software
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
EP2611445B1 (en) * 2010-09-03 2018-08-15 Zoetis Belgium S.A. High dose buprenorphine compositions and use as analgesic
EP3791861A1 (en) 2012-07-26 2021-03-17 Camurus AB Opioid formulations
US9918981B2 (en) * 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens

Similar Documents

Publication Publication Date Title
JP2021511326A5 (https=)
JP2006513238A5 (https=)
JPH10152663A5 (https=)
JP2003213038A5 (https=)
DE10346913A1 (de) Acylhydrazonderivate
JP2009532529A5 (https=)
JP2011507736A5 (https=)
JP2003514758A5 (https=)
JP2008522981A5 (https=)
JP2008527091A5 (https=)
JP2004532847A5 (https=)
JPWO2019144079A5 (https=)
JP2007511047A5 (https=)
WO2005041934A3 (de) Pharmazeutische wirkstoffhaltige formulierung mit überzug
WO2008132552A3 (en) Omega-3 lipid compounds
JP2021533273A5 (https=)
CN115867545A8 (zh) 抗病毒素1,3-二氧代茚化合物
JP2007051233A5 (https=)
JP2003119143A5 (https=)
JP2007505905A5 (https=)
HUP0104562A2 (hu) Savegységgel rendelkező kopolimert tartalmazó hajrögzítő kozmetikai készítmény
JP2005146110A5 (https=)
JP2006508153A5 (https=)
JP2007536285A5 (https=)
JP2006188610A5 (https=)